Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT—Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment
Figure 5
Simulated globus pallidus manganese concentrations in humans following inhalation exposure to MnSO4 at 0.00005 (a) or 0.2 mg (b) Mn/m3 for 8 hr/d, 5 d/wk, for one year. Simulations were performed using the human model developed by Schroeter et al. [19] with the following exceptions: model simulations for humans with hepatobiliary impairment had a 50% decrease in liver blood flow and a 50% decrease in biliary excretion () to simulate moderate hepatobiliary disease (see text for more details).
